Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
CureVac N.V.
CureVac develops mRNA-based medicines and vaccines for infectious diseases, cancer, and protein therapies.
CureVac is a biotech company that designs medicines and vaccines using mRNA, the same genetic messenger technology that powered some of the fastest vaccines in history. Its focus is on three big areas: preventive vaccines that stop infectious diseases, cancer treatments that teach the immune system to attack tumors, and protein therapies that help the body make missing or faulty proteins. The idea is simple in concept but hard in practice: instead of delivering a drug from the outside, you give the body instructions to make the therapeutic protein itself.
The company is based in Tübingen, Germany, and it spent years as a publicly traded stock on the Nasdaq. That changed when GSK stepped in. GSK, the big British drugmaker, owns a large stake in CureVac and took control of its mRNA vaccine work, including a licensing deal worth up to roughly €1.45 billion plus milestones. Today CureVac is no longer a standalone listed company; its shares stopped trading, and GSK is the dominant owner shaping its future. The business model is classic biotech: spend heavily on research, partner with bigger players to fund late-stage trials, and earn money through licensing fees, milestone payments, and royalties if a product reaches the market. CureVac's mRNA platform is its key asset, and the bet is that its technology can produce vaccines and treatments more cheaply and quickly than traditional methods. That bet has been costly and uneven — its original COVID-19 vaccine candidate stumbled in late-stage trials, which is a big reason the company ended up leaning on GSK rather than going it alone.
For a curious observer, CureVac is worth watching because it sits at the intersection of cutting-edge science and hard commercial reality. mRNA is a powerful idea, but turning it into reliable products takes years and enormous cash. With GSK's backing, CureVac has a better shot at getting its pipeline across the finish line — but it also means the upside now gets shared with a much larger partner.
Saved answer · last researched 14 Nov 2026